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We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC)
considering BRCA1, BRCA2, andRAD51C in a large well-annotated patient set.We evaluated EOCpatients
for germline deleterious mutations (n5 899), somatic mutations (n5 279) and epigenetic alterations (n5
482) in these genes using NGS and genome-wide methylation arrays. Deleterious germline mutations were
identified in 32 (3.6%) patients for BRCA1, in 28 (3.1%) for BRCA2 and in 26 (2.9%) for RAD51C. Ten
somatically sequenced patients had deleterious alterations, six (2.1%) in BRCA1 and four (1.4%) in BRCA2.
Fifty two patients (10.8%) had methylated BRCA1 or RAD51C. HRD patients with germline or somatic
alterations in any gene were more likely to be high grade serous, have an earlier diagnosis age and have
ovarian and/or breast cancer family history. The HRD phenotype was most common in high grade serous
EOC. Identification of EOC patients with an HRD phenotype may help tailor specific therapies.
O
varian cancer represents the fifth most common cause of cancer mortality in women due in part to the
advanced stage at which patients typically present, with an estimated 14,030 deaths and 22,240 cases in
2013 in the United States1. The most common ovarian cancer is invasive epithelial ovarian cancer, with
five common histological subtypes: high grade serous (70%), endometrioid (10%), clear cell (10%), low grade
serous (5%), andmucinous (3%). A family history of breast or ovarian cancer in first degree relatives increases the
risk for ovarian cancer2; family-based studies have revealed high- and moderate-penetrance genes including
BRCA13, BRCA24, DNAmismatch repair genes5,RAD51C6,7,RAD51D8 and BRIP16, and case-control studies have
identified eleven common variants associating with modestly increased risks9–15. Estimates of the contribution of
germline BRCA1 and BRCA2mutations to EOC vary widely from 5% to 20%16; somatic mutations in BRCA1 and
BRCA2 occur less frequently (in 2%–8% patients)17,18 and, as has BRCA1methylation19–22 have been reported in
ovarian cancer patients with no family history23.
Ovarian cancer patients who are BRCA1 and BRCA2 germline mutation carriers have been reported to have an
improved outcome compared to non-carriers and the mechanism underlying this benefit has been hypothesized
as a high response rate to platinum agents, particularly among patients with high grade serous histology24–27. This
is because patients with germline BRCA1 or BRCA2mutations have an impaired ability to repair double stranded
DNA breaks through homologous recombination28. More recently, favorable responses to poly (adenosine
diphosphate-ribose) polymerase (PARP) inhibitors have been noted in ovarian cancer patients carrying dele-
terious germline BRCA1 and BRCA2 mutations29. However, some ovarian cancer patients without germline
BRCA1 and BRCA2mutations also respond to PARP inhibitors30, suggesting that broader dysfunction of homo-
logous recombination than BRCA1 and BRCA2, a homologous recombination deficient (HRD) phenotype may
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be important. HRD may be the result of deleterious germline muta-
tion in other homologous recombination genes such as RAD51B,
RAD51C, or RAD51D or somatic mutation or silencing of the same
homologous recombination genes31,32
We evaluated the prevalence of HRD in a large EOC case series
and correlated this with clinical outcomes. HRD was determined by
sequencing BRCA1, BRCA2 and RAD51C in germline and tumor
DNA and assessing DNA methylation of cytosines at CpG sites
surrounding these genes.
Results
Table 1 shows the characteristics of patients and Figure 1 shows the
number of samples with each data type, after QC exclusions,
included in this analysis.
Frequency of methylation, germline and somatic mutations. Of
the 899 germline-tested patients, deleterious mutations were seen in
83 (9%): 32 (3.5%) in BRCA1, 28 in BRCA2 (3%), and 26 in RAD51C
(2.9%; Table 2). Three cases carried mutations in more than one
gene: two patients carried deleterious mutations in BRCA1 and
RAD51C, and one carried deleterious mutations in BRCA2 and
RAD51C. For the 619 HGS cases, deleterious mutations were seen
in 69 (11%), 27 (4%) in BRCA1, 24 (4%) in BRCA2 and 19 (3%) in
RAD51C. One HGS patient carried a mutation in both BRCA2 and
RAD51C. Of the six Ashkenazi Jewish patients, one carried a
germline BRCA1 mutation (C61G) and none carried either somatic
mutations or methylation. Table S1 and S2 provides a complete
mutation listing, after exclusions (see Methods section). Another
187 women carried germline missense mutations, none of which
had evidence for pathogenicity in the key clinical databases, 65 of
these alterations were in BRCA1, 102 in BRCA2 and 32 in RAD51C.
Twelve patients had a missense mutation in multiple genes. These
variants were considered variants of unknown significance (VUS). In
the patients with deleterious mutations, 13 patients also had a
missense VUS that was identified. The remaining 629 patients had
no deleterious or missense VUS mutations in BRCA1, BRCA2 or
RAD51C.
Two hundred and seventy nine patients with available tumor tis-
sue were screened for somatic mutations. Ten tumors (4%) were
found to have deleterious somatic mutations, six in BRCA1, and four
in BRCA2 (Table 2). Table S2 provides a complete listing for the
somatic mutations. Missense VUS were also detected with one in
BRCA1 and one in BRCA2. Two hundred and sixty seven patients
had no deleterious or missense VUS mutations detected. No dele-
terious somatic variations were identified in RAD51C.
Forty five of 482 tumors (9%) exhibited a methylated BRCA1
phenotype, and seven tumors (1%) showed RAD51C methylation
(Table 2). BRCA1 methylation was not detected in any individual
carrying a germline BRCA1 deleterious mutation; similarly, RAD51C
methylation was exclusive of germline RAD51C mutation carrier
status. However, there were two patients with amutation andmethy-
lation of another gene; one patient had a somatic mutation in
BRCA2 and BRCA1 methylation and another carried a germline
RAD51C mutation and had methylated BRCA1.
Clinical and pathological analyses. In combination, 143 patients
exhibited a HRD phenotype (82 due to germline mutation only,
nine due to somatic mutation only, 50 due to tumor methylation
only, one due to germline mutation and methylation, and one
additional due to somatic mutation and methylation, Table 2). A
total of 79 HRD patients showed alterations in BRCA1, 30 in
BRCA2, 29 in RAD51C and five patients showed alterations in
more than one gene.
We examined the clinical features of HRD compared to patients
with no abnormality detected (NAD) for those with both germline
and somatic data (Tables 3, S3). HRD patients had younger age at
diagnosis (P5 0.0001) and were more likely to be high grade serous
(118/264, P5 0.0004) and have a family history of breast or ovarian
Table 1 | Clinical characteristics of epithelial ovarian cancer
patients (N 5 1063)
N (%)
Mean age at diagnosis, years (SD) 62.4 (11.7)
Histology
High-grade serous 735 (70%)
High grade endometrioid 73 (7%)
Low grade endometrioid 67 (6%)
Clear Cell 69 (7%)
Low-grade serous 34 (3%)
Mucinous 29 (3%)
Other/Unknown 56
FIGO Stage
I 158 (15%)
II 62 (6%)
III 637 (61%)
IV 194 (19%)
Unknown 12
Debulking category
Optimal 848 (85%)
Sub-optimal 150 (15%)
Unknown 65
Grade
Low grade 143 (14%)
High grade 896 (86%)
Unknown 24
Menopause status
Pre-menopausal/peri-menopausal 169 (20%)
Post-menopausal 672 (80%)
Unknown 222
Ascites present at surgery
Yes 524 (63%)
No 307 (37%)
Unknown 232
Ashkenazi ancestry
Yes 6 (1%)
No 498 (99%)
Unknown 559
Median survival, years (range) 2.9 (0.01–10)
Median follow-up time among living, years (range) 4.5 (0.01–10)
Deaths 638 (60%)
N (%), unless otherwise specified.
Figure 1 | Venn diagram representing data availability for N 5 1063
invasive EOC patients.
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cancer (P 5 0.002) than patients with NAD. Interestingly, patients
with high grade (10/27) endometrioid EOC were HRD, compared to
2/23 patients with low grade endometrioid EOC. One of the most
common pathology challenges is whether high grade endometrioid
are in fact high grade serous EOC33. Other covariates (debulking,
peritoneal cytology, the presence of ascites and smoking and alcohol
use history) were not significantly different between the two groups.
We also examined clinical features within the HRD patients and
found only family history of breast or ovarian cancer was more
common in mutated than methylated patients (P 5 0.0001, data
not shown).
Survival analyses were carried out on those patients withHRD and
those with NAD for which all data (germline, somatic mutation and
methylation) were available (n5 356). Forty percent (143/356) of all
the patients were HRD, while 44.7% (118/264) of HGS patients were
HRD. Overall survival for all patients was associated with the HRD
phenotype (adjusted HR 0.73, 95% CI 0.54–0.98, P5 0.04, Table 4),
but not within each of the defective classes, genes that were mutated
at the germline or somatic level or were somatically methylated
(respectively, adjusted HR 0.81, 95% CI 0.57–1.15; adjusted HR
0.56, 95% CI 0.20–1.54, adjusted HR 0.65, 95% CI 0.42–1.02, P 5
0.18, Table 4), or when outcomes were examined by germline muta-
tion carrier status (P 5 0.09, Table 4). The hazard ratios data are
similar to those previously reported in a large germline study26.
Results were similar whether VUS were included in the NAD cat-
egory or excluded (data not shown). Analysis of time to recurrence
showed no association with any of the HRD phenotypes (Table S3).
Survival analyses were also conducted restricted to high grade serous
(n 5 618 for germline carrier analysis, 264 for HRD analysis) and
showed an overall survival differences between HRD and NAD
(adjusted HR 0.70, 95% CI 0.51–0.97, P 5 0.03, Table 4, Figure 2),
but not between germline mutation carriers and-non carriers
(adjusted HR 1.07, 95% CI 0.65–1.76; adjusted HR 0.76, 95% CI
0.45–1.30, adjusted HR 0.66, 95% CI 0.37–1.18, P 5 0.40, Table 4,
Figure 2). Survival at 5 years was similar (adjusted HR 0.68 95% CI
0.48, 0.97, P5 0.04, data not shown). Analysis of time to recurrence
was null (Table S4, Figure S3). Finally, we examined HRD pheno-
types by debulking status in germline mutation carriers, as Alsop
et al27 reported that improved survival was not evident in patients
that were sub-optimally debulked. However, we observed no differ-
ence in germline mutation carriers stratified by debulking status
(data not shown).
Discussion
Using a large homogeneous collection of ovarian cancer patients
with clinical follow up unselected for family history, we evaluated
Table 2 | Summary of germline mutations, somatic mutations, and methylation of BRCA1, BRCA2 and RAD51C
N Tested
Gene, n
Combined HRDBRCA1 BRCA2 RAD51C
Germline deleterious mutation 899 32 28 26 83
Somatic deleterious mutation 279 6 4 0 10
Methylated 482 45 - 7 52
No deleterious mutation, not methylated NA 237 261 263 NA
No deleterious germline mutation, unknown somatic mutation
and/or tumor methylation status
NA 592 606 604 NA
Not methylated, germline and somatic mutation status unknown NA 151 164 163 NA
Total 1063 1063 1063 143
Deleterious mutations were frame shift insertion/deletion, splice site, rare missense supported by multiple methods to be damaging; NA, not applicable; one case carried germline deleterious mutations for
both BRCA2 and RAD51C, and two patients carried germline deleterious mutations for BRCA1 and RAD51C, thus the combined number of germline deleterious mutation carriers is less than the sum of
mutation carriers for each gene; one case carried a RAD51C germline deleterious mutation and methylated for BRCA1 and another case carried a BRCA2 somatic deleterious mutation and methylated for
BRCA1, thus the total number of patients with a HRD phenotype is less than the sum of germline mutation carriers and patients with a somatically mutated or methylated gene.
Table 3 | Comparison of the clinical characteristics of HRD to NAD patients
HRD (n 5 143) NAD (n 5 213) P value
Age at Diagnosis, years 0.0001
Mean (SD) 58.4 (10.6) 63.1 (11.5)
Histology 0.0004
High grade serous 118 (45%) 146 (55%)
High grade endometrioid 10 (37%) 17 (63%)
Low grade endometrioid 2 (9%) 21 (91%)
Clear Cell 5 (28%) 13 (72%)
Low grade Serous 2 (15%) 11 (85%)
Mucinous 0 (0%) 5 (100%)
Other/Unknown 6 (100%) 0 (0%)
Grade ,0.0001
High 135 (44%) 174 (66%)
Low 5 (11%) 39 (89%)
Unknown 3 (100%) 0 (0%)
First Degree Family History of Breast or Ovarian Cancer 0.0020
No 104 (36%) 183 (64%)
Yes 39 (57%) 30 (43%)
First Degree Family History of Ovarian Cancer 0.0344
No 132 (39%) 207 (61%)
Yes 11 (65%) 6 (35%)
Only patients with known HRD status (germline mutation, somatic mutation and somatic methylation) available were included; VUS carriers are included in NAD patient group; stage, debulking, presence of
ascites, peritoneal cytology, smoking history, enrollment year, alcohol use were not significantly different between HRD and NAD patients.
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the clinical and pathological characteristics associated with a variety
of HRD phenotypes. Deleterious germline mutations in BRCA1,
BRCA2 or RAD51C were seen 9% of the subjects, BRCA1 or BRCA2
in 6.7% which is within the ranges of those previously reported (5.8%-
13.2%)16. Somatic mutations were less common (3.6%), but 11% of the
tumors analyzed exhibited BRCA1 or RAD51C methylation, compar-
able to the prevalence observed in 319 high grade serous ovarian
cancers analyzed by the Cancer Genome Atlas19. In total, 143 of the
patients had an HRD phenotype. A common phenotype has been
reported for sporadic cancers that share the characteristics of tumors
associated with germline BRCA1 and BRCA2 mutations34,35, and
includes RAD51C in which germline mutations have been identified
in patients of familial breast and ovarian cancer6,36,37, as has methyla-
tion38,39. Additionally, Abkevich et al40 report an LOH-based score for
HRD which included promoter methylation of RAD51C. Here, we
analyzed patients regardless of family history, included germline as
well as tumor testing for more comprehensive analysis and defined
patients as HRD if any deleterious alterations in BRCA1, BRCA2 and
RAD51C genes were found.
An HRD phenotype was seen in 45% of high grade serous EOC
(69% of patients had HGS EOC), with a smaller proportion
observed in low grade serous and the other histologies. This is
consistent with observations of others19,26,27. While we did observe
a survival advantage for those patients with an HRD phenotype,
analysis did not reveal any overall survival differences between
BRCA1 or BRCA2 mutation carriers and non-carriers, unlike prior
studies. This was unexpected given the literature suggesting longer
progression free survival or overall survival for EOC in mutation
carriers; however, this advantage appears to be short term. Most
studies were out to 60 months only and McLaughlin et al41 showed
that an early (up to five years) survival benefit was not evident
beyond eight years41. Similarly we do not show a long term sur-
vival advantage, thus follow up time may explain the apparent
discordance. It may also be that the number of germline BRCA1
and BRCA2 mutations carriers was too small and thus underpow-
ered. Additionally, while care was taken to classify the mutations
according to the best available evidence, the power of our analysis
will have been reduced by any misclassification of HRD. While the
TCGA concluded that methylated patients more closely match
survival in wild type BRCA patients, we observed that methylated
cases may have a survival benefit similar to that of the germline
mutation patients. All categories, while not reaching statistical
significance, showed a trend towards a survival benefit; had
methylation not been thus, then combining with mutation positive
patients would have biased the testing procedure towards the null.
Biologically, BRCA1 inactivated by methylation would result in a
similar defect as a deleteriously mutated allele. Our study involves
patients at one site, and all data were similarly processed while the
TCGA study involves samples from multiple centers with multiple
data sets, which may also account for the differences.
The high frequency of HRD defects in high grade serous EOC
suggest screening for this phenotype should be considered in clinical
care, particularly for new therapies, such as the PARP inhibitors that
may be most efficacious within this phenotype.
Strengths of this report include detailed methylation phenotyping
of a subset of patients and sequencing of tumor DNA. Limitations
include lack of methylation and somatic mutation data on up to 67%
of patients, not confirming the detected mutations in every patient
and inclusion of only three of more than ten genes now considered to
contribute to theHRDphenotype42. It is also critical to note thatmost
of these patients were treated with the current standard of care at
time of diagnosis (carboplatin and/or taxane); upcoming studies will
focus on those treated with PARP inhibitors. Other future work
includes sequencing of additional DNA repair genes in order tomore
comprehensively identify those patients with defective homologous
recombination pathway abnormalities.T
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Methods
Patient population and biospecimens. Women with EOC (n 5 1063) provided
written informed consent between 1992 and 2011 using IRB approved processes at
the Mayo Clinic in Rochester, MN. Use of patient derived samples in this study was
also approved and the work described was carried out in accordance with these
approved guidelines. Eligible participants were women aged 20 years or older with
diagnosis of pathologically confirmed invasive primary epithelial ovarian, fallopian
tube or primary peritoneal cancer. Patients were followed for vital status using
electronic medical records and linkage to vital statistics sources; the median time of
follow upwas 4.5 years, with a range of 0.1–10 years. Most patients were treated with a
platinum agent (carboplatin or cisplatin) and taxane, the standard of care at time of
diagnosis. Diagnosis (histology and grade) were reviewed by a gynecologic
pathologist. Peripheral blood (n 5 899) was used a source of germline DNA43. Pre-
chemotherapy tumor tissue (up to n5 482) was snap frozen immediately following
surgery and stored at280uC; tumor DNA was prepared from cryostat sections using
Qiagen PureGene chemistry (Qiagen Inc, Valencia, CA, USA) and quantitated using
Trinean (Trinean, Gentbrugge, Belgium). Tumor RNAwas isolated from fresh frozen
samples using the Qiagen RNEasy protocol (Qiagen Inc, Valencia, CA, USA) and
quantitated using a Nanodrop Spectrophotomer (Agilent Technologies, Santa Clara,
CA, USA). Somatic methylation analyses preceded the mutation screening, thus
samples with insufficient DNA for both analyses were not sequenced.
DNA sequencing and bioinformatics. Germline DNA (n 5 899, 1.25 ml DNA at a
concentration 75 ng/ml) and tumor DNA (n5 279) were sequenced at the University
of Cambridge, Cambridge, UK at BRCA1, BRCA2 and RAD51C. The procedure
entailed design of PCR primers, testing and optimization using Fluidigm Access
Array (FluidigmCorp., San Francisco, CA,USA). Briefly, themethod used a 4-primer
amplicon-tagging scheme. Tagged, target-specific primer pairs were combined with
sample-specific primer pairs that contained barcoding sequences and the adaptor
sequences used by the Illumina sequencing system. Using sample-specific barcodes,
all PCR products generated in the 48.48 Access Array Integrated Fluidic Circuit were
unique and pooled together to run in a single sequencing experiment. Sequencing
reactions were carried out on an Illumina GAIIX next-generation sequencer
(Illumina, Inc., San Diego, CA, USA).
GENOME_GPS 1.0 was used for analysis of DNA sequence data including read
alignment, variant detection, and annotation (Figure S1). Reads were aligned to
genome build hg19 using Novoalign and realignment, recalibration used the Genome
Analysis Toolkit (GATK) v.1.6.744. The percent of readsmapped on target was used to
exclude seven germline samples with,80% of amplicons covered at 203 and twenty
one tumor samples with ,80% of the amplicons covered at 203. To avoid false-
negative deleterious carrier status assignments for the somatic mutation data, non-
carrier patients were excluded if either germline or tumor sequencing data exhibited
,80% on-target sequence coverage at 203 or greater [mean coverage, 1st and 3rd
quartiles: RAD51C 138.76 (121.68, 150.94); BRCA1 164.81 (142.59, 179.47); BRCA2
157.65 (133.68, 174.13); all three genes, 158.20 (136.06, 173.04)].
Germline variants were called through GATKUnified Genotyper. Germline filtering
used genotype quality greater than 20 and read depth greater than 20. Somatic single
nucleotide variants were called using SomaticSniper45, whereas insertions and deletions
were called by GATK Somatic Indel Detector44. Somatic variants were considered with
a depth of at least 203 coverage for the germline and tumor DNA at the given site as
well as a quality score $ 20 and excluded if close to indel calls, aligned to multiple
positions and/or occurred in a known repeat region. Indel calls required $ 10 sup-
porting tumor sequencing reads, and no reads supporting the indel in the germline.
Each variant was annotated using the Targeted RE-sequencing Annotation Tool
(TREAT)46. Missense coding variants were functionally annotated by snpEFF (http://
snpeff.sourceforge.net/) and PolyPhen-2 to predict biological effects. Somatic
variants were considered deleterious if they were stop-gains (nonsense) or occurred at
splice sites junctions, along with frameshifts and insertion/deletions as deleterious. In
Figure 2 | Overall survival for high grade serous EOC by HRD and type of alteration. (A). Red: HRD; Black: NAD. (B). Above is a depiction of samples
with type of alteration in each gene; below are the Kaplan Meier curves. Red: germline deleterious mutation; Green: somatic deleterious mutation; Blue:
somatic methylation; Black: no germline mutation, somatic mutation or methylation.
www.nature.com/scientificreports
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addition, missense mutations were hand-curated using LOVD (www.LOVD.nl),
IARC (www.iarc.fr), HGMD (www.hgmd.cf.ac.uk), and Alamut (http://www.
interactive-biosoftware.com/software/alamut/features) databases. Variants for which
deleteriousness could not be determined with confidence, or which were known
polymorphisms, were considered VUS.
DNAmethylation.Tumormethylation status for 482 patients was examined using the
Illumina InfiniumHumanMethylation450 BeadChip as previously described47. Positive
bisulfite modified (BSM) controls (SssI treated DNA, CpGenome Universal Methylated
DNA, Millipore, Billerica, MA, USA, and placental DNA), negative BSM controls
(unmodified SssI treated DNA andWGADNA), and a CEPHDNA (Coriell Institute),
were included in each 96 well plate. Validation of nine CpG loci, including one at
BRCA1 (cg25288140), was accomplished by Pyrosequencing, as previously described47
and suggested that BeadChip data were satisfactory; Pearson correlation of methylation
values between BeadChip and Pyrosequencing assays ranged from 0.57 to 0.96.
To dichotomize tumor methylation status for each gene, we used expression array
data from 171 patients to identify CpG probes which negatively correlated with
expression. Expression data were generated using 750 ng of high quality total RNA
and Agilent Whole Human Genome 4 3 44K Expression Arrays (using a mixed
reference of 107 tumors) as previously described47. We estimated pairwise Spearman
correlations between gene expression and CpG methylation probes within 20 kb of
each gene to identify CpG probesmost associated with expression. For each probe, we
confirmed that each CpG probe was close to known promoter and active regulatory
elements defined by ENCODE project using the UCSC Genome Browser (Figure
S2A). Thresholds for dichotomization of methylation status were defined based upon
the medianmethylation value of the selected probe set. For example, Figure S2B plots
BRCA1 expression versus the median of N5 21 BRCA1 CpG probes; based on this,
patients with mean BRCA1 CpG methylation . 0.15 were considered BRCA1
methylated. A similar process was used for six CpG probes in RAD51C; however, no
BRCA2CpGwas clearly associated with altered gene expression, thus BRCA2was not
part of methylation analyses.
Association analysis. HRD patients were defined as those with deleterious
germline mutations, deleterious somatic mutations or methylation of BRCA1,
BRCA2, or RAD51C. Clinical characteristics of HRD and patients with NAD were
compared using Fisher exact tests. Survival analysis with HRD status was
conducted using multivariable Cox proportional hazards modeling and, for
adjusted analyses, included age, stage, debulking, menopausal status, grade, and
ascites, estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Time
at risk was defined from the date of diagnosis to date of death allowing for left
truncation with right censoring at last date of follow up to 10 years. In addition to
overall survival, we considered time-to-recurrence or death from any cause. We
analyzed survival using the HRD phenotype defined by germline status only and
also by combined germline, somatic, and methylation status (using the subset
with complete data). Analyses were for all patients and among patients with high
grade serous EOC and were conducted both with VUS considered to be non-
carriers or excluded. Each analysis used all available data (thus sample sizes vary)
and was implemented in SAS, with corresponding Kaplan-Meier curves
generated in R.
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